[{"id":"ad314edd-2963-47ac-86cd-5f06a81ee36e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06005649","created_at":"2023-08-22T15:08:54.438Z","updated_at":"2025-02-25T16:33:37.494Z","phase":"Phase 1/2","brief_title":"Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT06005649","lead_sponsor":"Juventas Cell Therapy Ltd.","biomarkers":" BCL2 • BCL6 • IL6 • CD22","pipe":" | ","alterations":" CD19 positive","tags":["BCL2 • BCL6 • IL6 • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • HY004"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-02-07"},{"id":"d7d0a6de-b0e3-4648-b4e9-ec298fd54104","acronym":"B-ALL","url":"https://clinicaltrials.gov/study/NCT06009107","created_at":"2024-03-13T08:35:11.520Z","updated_at":"2025-02-25T16:33:38.314Z","phase":"Phase 1/2","brief_title":"A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL)","source_id_and_acronym":"NCT06009107 - B-ALL","lead_sponsor":"Juventas Cell Therapy Ltd.","biomarkers":" IL6","pipe":" | ","alterations":" CD19 expression","tags":["IL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • HY004"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 06/30/2025","start_date":" 06/30/2025","primary_txt":" Primary completion: 12/30/2026","primary_completion_date":" 12/30/2026","study_txt":" Completion: 12/30/2027","study_completion_date":" 12/30/2027","last_update_posted":"2025-02-07"},{"id":"c91cce66-9863-44a5-bc73-cd92a627c3ae","acronym":"","url":"https://clinicaltrials.gov/study/NCT04034446","created_at":"2021-01-18T19:47:56.806Z","updated_at":"2024-07-02T16:36:06.186Z","phase":"Phase 1","brief_title":"CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)","source_id_and_acronym":"NCT04034446","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital","biomarkers":" CD22","pipe":" | ","alterations":" CD22 expression","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HY004"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 2","initiation":"Initiation: 09/30/2019","start_date":" 09/30/2019","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2022-08-03"}]